The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

Transcription

1 The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish Hospital Luling, Louisiana

2 Disclosures None

3 Overview Introduction Review antiplatelets drugs and actions Guidelines for use in CAD Use in PAD Future

4 Introduction Arterial thrombosis causes myocardial infarction, ischemic stroke, and acute limb ischemia. Platelets are maintained in an inactive state by healthy endothelial cells by production of nitric oxide and prostacyclin. Endothelial dysfunction caused by ruptured atherosclerotic plaques trigger platelet aggregation and fibrin formation leading to obstruction/occlusion!!

5 Introduction Antiplatelet Drugs Cornerstone of treatment for all cardiovascular diseases Showed to cause significant decreases in morbidity and mortality Lowers rates of stent thrombosis and restenosis Lowers recurrent events of ischemia, myocardial infarction, and stroke Increases unwanted bleeding Some with limitations in their use, i.e. surgery, past CVA, past ICH

6 Antiplatelets Drugs

7 Antiplatelets Mechanisms of Action

8 Antiplatelets in CAD

9 Table 1. Applying Class of Recommendation and Level of Evidence

10 Randomized Trials of DAPT Duration Trial Patients Test Randomization 1 EP Prolonged DAPT Studies REAL/ZEST Late DAPT PRODIGY Abbreviated DAPT Studies EXCELLENT ISAR-SAFE** ITALIC OPTIMIZE RESET 2701 DES N=20,645 (15,245 DES) (5,400 BMS) N=1,800 DES, BMS N=1,443 SES and EES N=6,000 DES N=3,700 EES N=3,120 ZES N=2,148 E-ZES vs RZES, SES, EES 1 vs. 2 yrs 1 vs. 2.5 yrs* 6 mos vs. 2 yrs 6 vs. 12 mos 6 vs. 12 mos* 6 vs. 12 mos 3 vs. 12 mos A vs. A+C Superiority A+P vs. DAPT (clop or pras) NI and Sup A vs. A+C Superiority A vs. A+C Noninferiority A+P vs. A+C Noninferiority A vs. A+C Noninferiority A vs. A+C Noninferiority 3 vs. 12 mos A+C vs. A+C D/MI 2 yrs after rand D/MI/CVA ST, Bleeding D/MI/CVA D/MI/TVR D/MI/CVA/ ST/TIMI MB D/MI/CVA/ Urg Revasc/MB D/MI/CVA/MB CVD/MI/ST/ ID-TVR, Bleed Strategy not DAPT duration ** *Plus a 3 month washout period

11 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American Society of Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons Endorsed by Preventive Cardiovascular Nurses Association and Society for Vascular Surgery American College of Cardiology Foundation and American Heart Association

12 Citation Adapted from the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Published on March 29 th, 2016, available at: Journal of the American College of Cardiology and Circulation The full-text guidelines are also available on the following Web sites: ACC ( and AHA (professional.heart.org).

13 Figure 1. Master Treatment Algorithm for Duration of P2Y 12 Inhibitor Therapy in Patients With CAD Treated With DAPT

14 Specific P2Y 12 Inhibitors COR LOE Recommendations IIa B-R In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation and in patients with NSTE-ACS treated with medical therapy alone (without revascularization), it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y 12 inhibitor therapy. IIa B-R In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation who are not at high risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel over clopidogrel for maintenance P2Y 12 inhibitor therapy. III: Harm B-R Prasugrel should not be administered to patients with a prior history of stroke or TIA.

15 Aspirin Dosing in Patients Treated With DAPT COR LOE Recommendation In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to I B-NR 100 mg) is recommended.

16 Percutaneous Coronary Intervention Duration of DAPT in Patients With SIHD Treated With PCI

17 Duration of DAPT in Patients With SIHD Treated With PCI COR LOE Recommendations In patients with SIHD treated with DAPT after BMS implantation, I A P2Y 12 inhibitor therapy with clopidogrel should be given for a minimum of 1 month. I B-R SR P2Y 12 inhibitor therapy with clopidogrel should be given for at least 6 months. In patients with SIHD treated with DAPT after DES implantation, I B-NR In patients treated with DAPT, the recommended daily dose of aspirin is 81 mg (range, 75 mg to 100 mg). SR indicates systematic review.

18 Duration of DAPT in Patients With SIHD Treated With PCI (cont d) COR LOE Recommendations IIb A SR In patients with SIHD treated with DAPT after BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or longer than 6 months in patients treated with DES may be reasonable. IIb C-LD In patients with SIHD treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop significant overt bleeding, discontinuation of P2Y 12 inhibitor therapy after 3 months may be reasonable. SR indicates systematic review.

19 Percutaneous Coronary Intervention Duration of DAPT in Patients With ACS Treated With PCI

20 Duration of DAPT in Patients With ACS Treated With PCI COR LOE Recommendations In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after BMS or DES I B-R implantation, P2Y 12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) should be given for at least 12 months. I IIa B-NR B-R In patients treated with DAPT, the recommended daily dose of aspirin is 81 mg (range, 75 mg to 100 mg). In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation, it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y 12 inhibitor therapy. IIa B-R In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation who are not at high risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel over clopidogrel for maintenance P2Y 12 inhibitor therapy.

21 Duration of DAPT in Patients With ACS Treated With PCI (cont d) COR LOE Recommendations IIb A SR In patients with ACS (NSTE-ACS or STEMI) treated with coronary stent implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 12 months may be reasonable. IIb C-LD In patients with ACS treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop significant overt bleeding, discontinuation of P2Y 12 inhibitor therapy after 6 months may be reasonable. III: Harm B-R Prasugrel should not be administered to patients with a prior history of stroke or TIA. SR indicates systematic review.

22 Acute Coronary Syndrome (NSTE-ACS and STEMI) Duration of DAPT in Patients With ACS Treated With Medical Therapy Alone

23 Duration of DAPT in Patients With ACS Treated With Medical Therapy Alone COR LOE Recommendations In patients with ACS who are managed with medical therapy alone (without I B-R revascularization or fibrinolytic therapy) and treated with DAPT, P2Y 12 inhibitor therapy (either clopidogrel or ticagrelor) should be continued for at least 12 months. I IIa B-NR B-R In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended. In patients with NSTE ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) treated with DAPT, it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y 12 inhibitor therapy. IIb A SR In patients with ACS treated with medical therapy alone (without revascularization or fibrinolytic therapy) who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT for longer than 12 months may be reasonable. SR indicates systematic review.

24 2016 ACC/AHA Duration of DAPT Guideline Focused Update Perioperative Management Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT

25 Perioperative Management Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT COR LOE Recommendations I B-NR Elective noncardiac surgery should be delayed 30 days after BMS implantation and optimally 6 months after DES implantation. I C-EO In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y 12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y 12 platelet receptor inhibitor be restarted as soon as possible after surgery. IIa C-EO When noncardiac surgery is required in patients currently taking a P2Y 12 inhibitor, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.

26 Perioperative Management Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT (cont d) COR LOE Recommendations IIb C-EO Elective noncardiac surgery after DES implantation in patients for whom P2Y 12 inhibitor therapy will need to be discontinued may be considered after 3 months if the risk of further delay of surgery is greater than the expected risks of stent thrombosis. III: Harm B-NR Elective noncardiac surgery should not be performed within 30 days after BMS implantation or within 3 months after DES implantation in patients in whom DAPT will need to be discontinued perioperatively.

27 Vorapaxar: New PAR-1 Inhibitor Vorapaxar (Zontivity ) protease-activated receptor 1 (PAR-1) inhibitor; Firstin-class antiplatelet medication Approved January 2014 and prescribed with DAPT TRA 2 0 TIMI-50 trial (N=26,499) 13% reduction of MI, stroke, CV death and revascularization in patients with a previous MI or peripheral artery disease (v. placebo) Increased moderate or severe bleeding in 4.2% (v. 2.5% placebo); Black Box Warning: contraindicated with history of stroke, TIA and intracranial hemorrhage due to high-risk of bleeding Bhatt D L et al. Circulation Research. 2014;114:

28 Antiplatelets in PAD

29 Antiplatelets in PAD is a different beast PAD (symptomatic and asymptomatic) has high rate of CV events Antiplatetelt Trialists Collaboration and CAPRIE trials showed reduction in CV events with antiplatelets compared to aspirin alone. Clopidogrel greater than aspirin protection

30 2011 ACCF/AHA Focused Update of the Management of Patients With Peripheral Artery Disease Guideline (Updating the 2005 Guideline) Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Vascular Medicine and Society for Vascular Surgery American College of Cardiology Foundation and American Heart Association, Inc.

31

32

33

34

35

36 American Heart Journal, Volume 175, 2016, 86 93

37 Conclusion Antiplatelets are the cornerstone to reduce CV events in patients with CAD and PAD New guidelines on management of antiplatelets in CAD are established Duration of treatment with DAPT is still being investigated and requires risk vs benefit to each patient Future antiplatelet studies and drugs are to come.

38 The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish Hospital Luling, Louisiana